| breast cancer - HER2-positive | breast cancer - HR positive | |
| la/mBC - HER2 positive - 2nd Line (L2) | la/mBC - HR-positive - 1st line (L1) | |
| lapatinib based treatment | ||
| lapatinib plus capecitabine | ||
| lapatinib plus fulvestrant | ||
| lapatinib plus letrozole | ||
| lapatinib plus trastuzumab | EGF104900 |